Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Evangelos Stelios Gragoudas, M.D.

Co-Author

This page shows the publications co-authored by Evangelos Gragoudas and Anthony Adamis.
Connection Strength

0.542
  1. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30; 351(27):2805-16.
    View in: PubMed
    Score: 0.075
  2. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003 Aug 04; 198(3):483-9.
    View in: PubMed
    Score: 0.068
  3. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):290-9.
    View in: PubMed
    Score: 0.066
  4. Diffusion of high molecular weight compounds through sclera. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1181-5.
    View in: PubMed
    Score: 0.054
  5. Transscleral delivery of bioactive protein to the choroid and retina. Invest Ophthalmol Vis Sci. 2000 Apr; 41(5):1186-91.
    View in: PubMed
    Score: 0.054
  6. Systemic hyperoxia decreases vascular endothelial growth factor gene expression in ischemic primate retina. Arch Ophthalmol. 1997 Dec; 115(12):1553-8.
    View in: PubMed
    Score: 0.046
  7. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 1996 Nov; 103(11):1820-8.
    View in: PubMed
    Score: 0.043
  8. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol. 1996 Aug; 114(8):964-70.
    View in: PubMed
    Score: 0.042
  9. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996 Jan; 114(1):66-71.
    View in: PubMed
    Score: 0.040
  10. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jun; 44(6):2743-9.
    View in: PubMed
    Score: 0.017
  11. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002 Mar; 120(3):338-46.
    View in: PubMed
    Score: 0.015
  12. Angiography of fluoresceinated anti-vascular endothelial growth factor antibody and dextrans in experimental choroidal neovascularization. Arch Ophthalmol. 2000 Jan; 118(1):78-84.
    View in: PubMed
    Score: 0.013
  13. Systemic antiangiogenic therapy for choroidal neovascularization. What is the role of interferon alfa? Arch Ophthalmol. 1992 Oct; 110(10):1383-4.
    View in: PubMed
    Score: 0.008
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.